4//SEC Filing
MANIAN BALA S 4
Accession 0001415889-25-004757
CIK 0001746466other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 7:35 PM ET
Size
26.2 KB
Accession
0001415889-25-004757
Insider Transaction Report
Form 4
MANIAN BALA S
Director
Transactions
- Award
Director Stock Option (right to buy)
2025-02-14+12,000→ 12,000 totalExercise: $0.79Exp: 2029-06-10→ Common Stock (12,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−12,000→ 0 totalExercise: $6.01Exp: 2029-06-10→ Common Stock (12,000 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+24,000→ 24,000 totalExercise: $0.79Exp: 2030-05-18→ Common Stock (24,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−24,000→ 0 totalExercise: $2.80Exp: 2030-05-18→ Common Stock (24,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−20,634→ 0 totalExercise: $3.53Exp: 2030-05-27→ Common Stock (20,634 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+20,770→ 20,770 totalExercise: $0.79Exp: 2031-05-25→ Common Stock (20,770 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−20,770→ 0 totalExercise: $6.55Exp: 2031-05-25→ Common Stock (20,770 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+20,000→ 20,000 totalExercise: $0.79Exp: 2032-05-23→ Common Stock (20,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−20,000→ 0 totalExercise: $2.59Exp: 2032-05-23→ Common Stock (20,000 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+20,634→ 20,634 totalExercise: $0.79Exp: 2030-05-27→ Common Stock (20,634 underlying)
Footnotes (6)
- [F1]The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F2]On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.
- [F3]The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F4]The shares subject to this option became fully vested on the grant date of May 28, 2020.
- [F5]These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F6]The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
Documents
Issuer
Equillium, Inc.
CIK 0001746466
Entity typeother
Related Parties
1- filerCIK 0000941871
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 7:35 PM ET
- Size
- 26.2 KB